Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Dustin Deming
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06493019CT.gov Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | — | Recruiting | — | — | — |
NCT05544929CT.gov A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | — | Active Not Recruiting | — | — | — |
NCT04357873CT.gov Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations | — | Completed | — | — | — |
NCT04046133CT.gov Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus | — | Active Not Recruiting | — | — | — |
NCT04234113CT.gov Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT02919969CT.gov Pembrolizumab in Metastatic Anal Cancer | — | Completed | — | — | — |
NCT02628067CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Dustin Deming | P2 | B · 59 |
| Fluorouracilum | Federation Francophone de Cancerologie Digestive | P3 | BB |
| Carboplatin | Dustin Deming | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P3 | BB |
| Muamycin | Federation Francophone de Cancerologie Digestive | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Federation Francophone de Cancerologie Digestive | P3 | BB |
| Cyclophosphamide | Christian Hinrichs | P2 | BB |
| Oxaliplatin | University of Cincinnati | P2/3 | B |
+42 more in the Anal Carcinoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Anal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-anal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →